Race Oncology is an Australian clinical stage, biopharmaceutical company with a dedicated mission to be at the heart of cancer care.
The company's focus is on addressing the high unmet need of cancer patients for better and less damaging treatments that leverage the unique activity of its lead drug, RC220 bisantrene. RC220 is a propriety reformulated version of bisantrene, designed for improved safety and clinical utility.
